Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Apnimed logo — Apnimed is a clinical-stage company advancing oral medicines...

Apnimed

Apnimed is a clinical-stage company advancing oral medicines to treat Obstructive Sleep Apnea and related disorders.

Founded 2017 United States Cambridge, United States 74 employees Series C Total: $207.83M Health Care, Medical Devices

General Information

Company Name Apnimed
Founded Year 2017
Location United States Cambridge, United States
Founders / Decision Makers
Team member Team member
Employees 74
Industries Health Care, Medical Devices
Funding Stage Series C
Social

BounceWatch is an independent company data service, not affiliated with Apnimed. To contact Apnimed, visit apnimed.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Apnimed compare?

A PDF of Apnimed and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Apnimed soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Apnimed

Apnimed is a clinical-stage company founded in 2017, with a focus on advancing oral medicines to address Obstructive Sleep Apnea (OSA) and related disorders. The company's slogan sums up its mission succinctly: "Apnimed is a clinical-stage company advancing oral medicines to treat Obstructive Sleep Apnea and related disorders." This reflects the company's commitment to developing innovative solutions for a pressing healthcare issue. Based in the United States, Apnimed recently secured a substantial $79.75M Series C investment on 23 December 2022. The investment came from a consortium of well-regarded investors including Tao Capital Partners, Alpha Wave Global, Sectoral Asset Management, and Alpha Wave Ventures. This funding will likely enable Apnimed to advance its clinical-stage programs and drive further innovation in the treatment of OSA and related disorders.

Business keywords: clinical-stage company, oral medicines, Obstructive Sleep Apnea, OSA, sleep disorders, pharmaceuticals, drug development, clinical trials, pharmaceutical industry

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Series C $79.75M 4
Tao Capital Partners Alpha Wave Global Sectoral Asset Management
Tao Capital Partners, Alpha Wave Global +2
23 Dec 2022
Series C $62.50M 5
Morningside Ventures Tao Capital Partners Alpha Wave Global
Morningside Ventures, Tao Capital Partners +3
04 May 2022
Series B $25.00M 1
Morningside Venture Investments
25 Mar 2021
Venture Round $15.00M -
31 Mar 2020
Venture Round $25.58M -
25 Jun 2018

Apnimed Alternatives & Competitors

View All Alternatives
Apnimed vs
Inspire Medical Systems
Inspire Medical Systems United States

We are committed to elevating and redefining the standard of care for Obstructive Sleep Apnea.

Post-IPO Equity
1195 employees
Biotechnology, Health Care
Apnimed vs
ZOLL Itamar
ZOLL Itamar United States

Home Sleep Apnea Test and Digital Health Company.

Post-IPO Secondary
310 employees
Health Care, Medical Devices
Apnimed vs
LinguaFlex LLC
LinguaFlex LLC

Redefining Sleep Health with Innovative Technology for Obstructive Sleep Apnea Treatment

Venture round
6 employees
Biotechnology, Health Care
View all alternatives

FAQ About Apnimed

Apnimed is a clinical-stage company advancing oral medicines to treat Obstructive Sleep Apnea and related disorders.
Apnimed was founded in 2017.
Apnimed is headquartered in Cambridge, United States.
Apnimed operates in Health Care and Medical Devices. Its work centres on clinical-stage company, oral medicines, Obstructive Sleep Apnea and OSA.
Apnimed has approximately 74 employees.
Apnimed has completed 5 funding rounds, raising a total of $207.83M. The latest funding stage is Series C.
Top alternatives and competitors to Apnimed include Inspire Medical Systems, ZOLL Itamar, LinguaFlex LLC, Zelegent, Himuka AM Pharma / Himuka AM Australia. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Apnimed and Inspire Medical Systems are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Apnimed, https://bouncewatch.com/company/apnimed, updated 30 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes